EX-10.33



 Exhibit 10.33 

Execution Version 

SUBSCRIPTION AGREEMENT 

This Subscription Agreement (this “Agreement”) is made as of June 2, 2014 by and among: 

 

	 	(1)	Zhaopin Limited, a company incorporated in the Cayman Islands (the “Company”); and 

  

	 	(2)	PCV Belge SCS, a company incorporated in Belgium (the “Purchaser”). The Purchaser on the one hand, and the Company on the other hand, are sometimes herein referred to each as a “Party,”
and collectively as the “Parties.” 

 W I T N E S S E
T H: 
 WHEREAS, the Company has filed a registration statement on Form F-1 on May 5, 2014 (as amended by Amendment 1
filed with the SEC on May 15, 2014, the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”) in connection with the initial public offering (the
“Offering”) by the Company of American Depositary Shares (“ADS”) representing Class A ordinary shares (“Ordinary Shares”) of the Company as specified in the Registration Statement; and 

WHEREAS, the Purchaser wishes to invest in the Company by acquiring Ordinary Shares in the Company in a transaction exempt from registration
pursuant to Regulation S (“Regulation S”) of the U.S. Securities Act of 1933, as amended (the “Securities Act”); 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises hereinafter set forth, the Parties hereto agree as follows:

 ARTICLE I 

PURCHASE AND SALE 

Section 1.1 Issuance, Sale and Purchase of Ordinary Shares. Upon the terms and subject to the conditions of this Agreement,
the Purchaser hereby agrees to purchase, and the Company hereby agrees to issue, sell and deliver to the Purchaser, at the Closing (as defined below), the number of Ordinary Shares determined pursuant to Section 1.2 (the “Purchased
Shares”) at a price per Ordinary Share equal to the Offer Price (as defined below), free and clear of all liens or encumbrances (except for restrictions arising under the Securities Act or created by virtue of this Agreement or the Lock-up
Agreement (as defined below). The total purchase price for the Purchased Shares is US$15 million (as adjusted pursuant to Section 1.2, the “Purchase Price”). The “Offer Price” means the price per ADS set forth
on the cover of the Company’s final prospectus in connection with the Offering (the “Final Prospectus”) divided by the number of Ordinary Shares represented by one ADS. The purchase, issuance, sale and delivery of the Purchased
Shares shall be made pursuant to and in reliance upon Regulation S. 







 Section 1.2 Closing. 

(a) Closing. Subject to Section 1.3, the closing (the “Closing”) of the sale and purchase of the Purchase Shares
pursuant to Section 1.1 shall take place concurrently with the closing of the Offering at the same offices for the closing of the Offering or at such other place as the Company and the Purchaser may mutually agree. The total number of the
Ordinary Shares that the Purchaser shall purchase from the Company as Purchased Shares at the Closing shall be equal to the quotient of the Purchase Price divided by the Offer Price; provided, however, that (i) no fractional
shares of Ordinary Shares will be issued as Purchased Shares, (ii) any fractions shall be rounded down to the nearest whole number of Ordinary Shares, and (iii) the Purchase Price will be reduced by the value of any such fractional share
(as calculated on the basis of the Offer Price). The date and time of the Closing are referred to herein as the “Closing Date.” 

(b) Payment and Delivery. At the Closing, the Purchaser shall pay and deliver the Purchase Price to the Company in U.S. dollars by wire
transfer, or by such other method mutually agreeable to the Company and the Purchaser, of immediately available funds to such bank account designated in writing by the Company, and the Company shall deliver one or more duly executed share
certificates in original form, registered in the name of the Purchaser, together with a certified true copy of the register of the members of the Company, evidencing the Purchased Shares being issued and sold to the Purchaser. 

(c) Restrictive Legend. Each certificate representing Purchased Shares shall be endorsed with the following legend: 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (AS AMENDED, THE “ACT”) OR UNDER THE SECURITIES LAWS OF ANY
STATE. THIS SECURITY MAY NOT BE TRANSFERRED, SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED: (A) IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, (2) AN EXEMPTION OR QUALIFICATION UNDER THE ACT AND OTHER
APPLICABLE SECURITIES LAWS OR (3) DELIVERY TO THE COMPANY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED; AND (B) WITHIN THE UNITED STATES OR TO ANY U.S. PERSON, AS EACH OF THOSE
TERMS IS DEFINED IN REGULATION S UNDER THE ACT, DURING THE 40 DAYS FOLLOWING CLOSING OF THE PURCHASE. ANY ATTEMPT TO TRANSFER, SELL, PLEDGE OR HYPOTHECATE THIS SECURITY IN VIOLATION OF THESE RESTRICTIONS SHALL BE VOID. 

Section 1.3 Closing Conditions. 

(a) Conditions to the Purchaser’s Obligations to Effect the Closing. The obligation of the Purchaser to purchase and pay for its
Purchased Shares as contemplated by this Agreement is subject to the satisfaction, on or before the Closing Date, of the following conditions, any of which may be waived in writing by the Purchaser in its sole discretion: 

(i) All corporate and other actions required to be taken by the Company in connection with the issuance, sale and delivery of
the Purchased Shares (including registration of such issuance of the Purchased Shares in the register of the members of the Company) shall have been completed. 

  
 2 








 (ii) The representations and warranties of the Company contained in
Section 2.1 of this Agreement shall have been true and correct on the date of this Agreement and true and correct in all material respects on and as of the Closing Date, except (x) the representations and warranties contained in
Section 2.1(a) to Section 2.1(g) and Section 2.1(i), and (y) the representations and warranties that are qualified by “material”, “Material Adverse Effect” or words of similar import,
shall be true and correct in all respects on the date of this Agreement and on and as of the Closing Date; and the Company shall have performed and complied in all material respects with all, and not be in breach or default in any material respects
under any, agreements, covenants, conditions and obligations contained in this Agreement that are required to be performed or complied with on or before the Closing Date. 

(iii) No governmental authority of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any law
(whether temporary, preliminary or permanent) that is in effect and restrains, enjoins, prevents, prohibits or otherwise makes illegal the consummation of the transactions contemplated by this Agreement, or imposes any damages or penalties in
connection with the transactions contemplated by this Agreement that are substantial in relation to the Company; and no action, suit, proceeding or investigation shall have been instituted by a governmental authority of competent jurisdiction or
threatened that seeks to restrain, enjoin, prevent, prohibit or otherwise make illegal the consummation of the transactions contemplated by this Agreement, or imposes any damages or penalties in connection with the transactions contemplated by this
Agreement that are substantial in relation to the Company. 
 (iv) The Offering shall have been, or shall concurrently with
the Closing be, completed. 
 (v) The ADSs shall have been listed on the New York Stock Exchange subject to official notice
of issuance. 
 (vi) The underwriting agreement relating to the Offering shall have been entered into and have become
effective. 
 (vii) The Offer Price will be no greater than US$7.25 per Ordinary Share (or US$14.50 per ADS assuming one ADS
represents two Ordinary Shares) and the Company will not issue more than 12,903,000 Ordinary Shares (represented by 6,451,500 ADSs assuming one ADS represents two Ordinary Shares) in the Offering (assuming full exercise of the underwriters’
over-allotment option). 

  
 3 








 (b) Conditions to Company’s Obligations to Effect the Closing. The obligation of the
Company to issue and sell the Purchased Shares to the Purchaser as contemplated by this Agreement is subject to the satisfaction, on or before the Closing Date, of each of the following conditions, any of which may be waived in writing by the
Company in its sole discretion: 
 (i) The Lock-up Agreement shall have been executed and delivered by the Purchaser to the
representatives of the underwriters for the Offering. 
 (ii) All corporate and other actions required to be taken by the
Purchaser in connection with the purchase of its Purchased Shares shall have been completed. 
 (iii) The representations and
warranties of the Purchaser contained in Section 2.2 of this Agreement shall have been true and correct in all material respects on the date of this Agreement and on and as of the Closing Date; and the Purchaser shall have performed and
complied in all material respects with all, and not be in breach or default in any material respect under any, agreements, covenants, conditions and obligations contained in this Agreement that are required to be performed or complied with on or
before the Closing Date. 
 (iv) No governmental authority of competent jurisdiction shall have enacted, issued, promulgated,
enforced or entered any law (whether temporary, preliminary or permanent) that is in effect and restrains, enjoins, prevents, prohibits or otherwise makes illegal the consummation of the transactions contemplated by this Agreement, or imposes any
damages or penalties in connection with the transactions contemplated by this Agreement that are substantial in relation to the Company; and no action, suit, proceeding or investigation shall have been instituted by a governmental authority of
competent jurisdiction or threatened that seeks to restrain, enjoin, prevent, prohibit or otherwise make illegal the consummation of the transactions contemplated by this Agreement, or imposes any damages or penalties in connection with the
transactions contemplated by this Agreement that are substantial in relation to the Company. 
 ARTICLE II 

REPRESENTATIONS AND WARRANTIES 

Section 2.1 Representations and Warranties of the Company. The Company hereby represents and warrants to the Purchaser, as
of the date hereof and as of the Closing Date, as follows: 
 (a) Due Formation. The Company is a company duly incorporated as an
exempted company with limited liability, validly existing and in good standing under the laws of the Cayman Islands. The Company has all requisite power and authority to carry on its business as it is currently being conducted. 

(b) Authority. The Company has full power and authority to enter into, execute and deliver this Agreement and each agreement,
certificate, document and instrument to be executed and delivered by the Company pursuant to this Agreement and to perform its obligations hereunder. The execution and delivery by the Company of this Agreement and any agreements, certificates,
documents and instruments to be executed and delivered by the Company pursuant to this Agreement, and the performance by the Company of its obligations hereunder, have been duly authorized by all requisite actions on its part. 

  
 4 








 (c) Valid Agreement. This Agreement has been duly executed and delivered by the Company
and constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of
general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 

(d) Capitalization. 

(i) The authorized share capital, option plans and issuance, warrant issuance and any other equity securities (including
securities convertible into or exercisable or exchangeable for equity securities) of the Company (the “Company Capitalization”) as of the date hereof is as set forth in Schedule D-1 of this Agreement, which includes the
ordinary shares and each series of convertible preferred shares (the “Preferred Shares”). All issued and outstanding ordinary shares and all issued and outstanding Preferred Shares are validly issued, fully paid and non-assessable.

 (ii) Upon effectiveness of the Closing and after giving effect to the Offering, the transactions contemplated by this
Agreement and other related transactions, the Company Capitalization will be as set forth in Schedule D-2 of this Agreement. Except as disclosed in Schedule D-1 or Schedule D-2 hereto, there are no options, warrants, convertible securities or
other rights, agreements, arrangements or commitments of any character relating to the Ordinary Shares or obligating the Company to issue or sell any Ordinary Shares, or any other interest in, the Company. Except as disclosed in the Registration
Statement, there will not be any split, combination or other restructuring with respect to any class of share capital of the Company after the date hereof and at or prior to the Closing. 

(iii) All outstanding shares of capital stock of the Company (including ordinary shares and Preferred Shares), all outstanding
awards under the Company’s stock option plans, all other outstanding warrants and other equity securities (including securities convertible into or exchangeable for equity securities) of the Company, and all outstanding shares of capital stock
of each of the Company’s subsidiaries and consolidated affiliates (each a “Subsidiary” and collectively “Subsidiaries”) have been issued and granted in compliance with (x) all applicable Securities Laws
and other applicable laws and (y) all requirements set forth in applicable plans or contracts, without violation of any preemptive rights, rights of first refusal or other similar rights. “Securities Laws” means the Securities
Act, the Securities Exchange Act of 1934, as amended, the listing rules of, or any listing agreement with the New York Stock Exchange and any other applicable law regulating securities or takeover matters. 

(iv)The rights of the Ordinary Shares to be issued to the Purchaser as Purchased Shares are as stated in the Tenth Amended and
Restated Memorandum and Articles of Association of the Company (the “Amended Articles”) as set out in Exhibit 3.2 of the Registration Statement, and there have not been any changes to the Amended Articles that adversely affect the
rights of the holders of the Purchased Shares as compared to any other holder of any class of ordinary shares. 

  
 5 








 (e) Due Issuance of the Purchased Shares. The Purchased Shares have been duly authorized
and, when issued and delivered to and paid for by the Purchaser pursuant to this Agreement, will be validly issued, fully paid and non-assessable and free and clear of any pledge, mortgage, security interest, encumbrance, lien, charge, assessment,
right of first refusal, right of pre-emption, third party right or interest, claim or restriction of any kind or nature, except for restrictions arising under the Securities Act or created by virtue of this Agreement or the Lock-up Agreement and
upon delivery and entry into the register of members of the Company will transfer to the Purchaser good and valid title to its Purchased Shares. 

(f) Noncontravention. Neither the execution and the delivery of this Agreement, nor the consummation of the transactions contemplated
hereby, will (i) violate any provision of the organizational documents of the Company or its Subsidiaries or violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any
government, governmental entity or court to which the Company or its Subsidiaries is subject, or (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of or creation of an encumbrance under, or create
in any party the right to accelerate, terminate, modify, or cancel, any agreement, contract, lease, license, instrument, or other arrangement to which the Company or its Subsidiaries is a party or by which the Company or its Subsidiaries is bound or
to which any of the Company’s or its Subsidiaries’ assets are subject. There is no action, suit or proceeding, pending or threatened against the Company or its Subsidiaries that questions the validity of this Agreement or the right of the
Company to enter into this Agreement or to consummate the transactions contemplated hereby. 
 (g) Consents and Approvals. Neither
the execution and delivery by the Company of this Agreement, nor the consummation by the Company of any of the transactions contemplated hereby, nor the performance by the Company of this Agreement in accordance with its terms requires the consent,
approval, order or authorization of, or registration with, or the giving notice to, any governmental or public body or authority or any third party, except such as have been or will have been obtained, made or given on or prior to the Closing Date.

 (h) Compliance with Laws. Except, as of the date hereof, as disclosed in the Registration Statement, and as of the Closing Date,
as disclosed in the Registration Statement in the form then declared effective by the SEC, the business of the Company or its Subsidiaries is not being conducted in material violation of any law or government order applicable to the Company. Within
the past three years, none of the Company or any of its Subsidiaries, or any of their respective directors or officers, or, to the knowledge of the Company, any of their respective employees, authorized agents, or any other person associated with or
acting on behalf of any of them, has conducted any act in violation of any applicable Anti-Corruption Laws, nor would they cause the Purchaser or any of its affiliates to be in violation of any applicable Anti-Corruption Law.
“Anti-Corruption Laws” means all the laws, regulations, conventions and international financial institution rules regarding corruption, bribery, ethical business conduct, money laundering, political contributions, gifts and
gratuities, or lawful expenses to public officials and private persons, agency relationships, commissions, lobbying, books and records, and financial controls. 

  
 6 








 (i) SEC Filings. Prior to the Closing, the Registration Statement, as supplemented or
amended, shall have been declared effective by the SEC. The Registration Statement, including the prospectus therein, conforms and the Registration Statement in the form in which it is declared effective by the SEC, will conform, in all material
respects to the requirements of the Securities Act and the rules and regulations of the SEC thereunder and the Registration Statement does not, as of the date hereof, and will not, as of the applicable effective date and in the form then on file
with the SEC, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. Except for pricing information for the Offering, the Registration
Statement, in the form in which it is declared effective by the SEC, will not contain any information that describes a fact, event, occurrence or result that is materially adverse to the Company and that is not described in the Registration
Statement. 
 (j) Investment Company. The Company is not and, after giving effect to the offering and sale of the Purchased Shares,
the consummation of the Offering and the application of the proceeds hereof and thereof, will not be an “investment company,” as such term is defined in the U.S. Investment Company Act of 1940, as amended. 

(k) Regulation S. No directed selling efforts (as defined in Rule 902 of Regulation S under the Securities Act) have been made by any
of the Company, any of its affiliates or any person acting on its behalf with respect to any Purchased Shares that are not registered under the Securities Act; and none of such persons has taken any actions that would result in the sale of the
Purchased Shares to the Purchaser under this Agreement requiring registration under the Securities Act; and the Company is a “foreign issuer” (as defined in Regulation S). The transactions contemplated under this Agreement will not
be integrated with the Offering pursuant to applicable rules and regulations issued under the Securities Act. 
 (l) Events Subsequent to
Most Recent Fiscal Period. Since June 30, 2013 until the date hereof and to the Closing Date, there has not been (i) any event, fact, circumstance or occurrence that has had or would reasonably be expected to have a Material Adverse
Effect, or (ii) any declaration, setting aside or payment of any dividends or other distribution with respect to any shares of share capital of the Company or any of its Subsidiaries except as disclosed under the section “Dividend
Policy” in the Registration Statement. As used herein, “Material Adverse Effect” shall mean any event, fact, circumstance or occurrence that, individually or in the aggregate with any other events, facts, circumstances or
occurrences, results in or would reasonably be expected to result in a material adverse change in or a material adverse effect on any of (i) the financial condition, assets, liabilities, results of operations, business, or operations of the
Company or its Subsidiaries taken as a whole, except to the extent that any such Material Adverse Effect results from (x) changes in generally accepted accounting principles that are generally applicable to comparable companies after the date
of this Agreement, or (y) changes in general economic and market conditions that do not adversely affect the Company and its Subsidiaries, taken as a whole, in a disproportionate manner as compared to other participants in the industry or
geographic markets in which the Company and its Subsidiaries operate; or (ii) the ability of the Company to consummate the transactions contemplated by this Agreement and to timely perform its obligations under the Agreement. 

(m) Litigation. There are no actions, suits, proceedings, inquiries or investigations by or against the Company or its Subsidiaries or
affecting the business or any of the assets of the Company or its Subsidiaries pending before any governmental authority, or, to the Company’s knowledge, threatened to be brought by or before any governmental authority, that is (x) as of
the date hereof, required to be disclosed in the Registration Statement (other than as disclosed therein), or as of the Closing Date, required to be disclosed in the Registration Statement in the form then on file with the SEC (other than as
disclosed therein), or (y) has had or would reasonably be expected to have a Material Adverse Effect. 

  
 7 








 Section 2.2 Representations and Warranties of the Purchaser. The Purchaser
hereby represents and warrants to the Company as of the date hereof and as of the Closing Date, as follows: 
 (a) Due Formation. The
Purchaser is duly formed, validly existing and in good standing in the jurisdiction of its organization. The Purchaser has all requisite power and authority to carry on its business as it is currently being conducted. 

(b) Authority. The Purchaser has full power and authority to enter into, execute and deliver this Agreement and each agreement,
certificate, document and instrument to be executed and delivered by the Purchaser pursuant to this Agreement and to perform its obligations hereunder. The execution and delivery by the Purchaser of this Agreement and any agreements, certificates,
documents and instruments to be executed and delivered by the Purchaser pursuant to this Agreement, and the performance by the Purchaser of its obligations hereunder have been duly authorized by all requisite actions on its part. 

(c) Valid Agreement. This Agreement has been duly executed and delivered by the Purchaser and constitutes the legal, valid and binding
obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of
creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 

(d) Noncontravention. Neither the execution and the delivery of this Agreement, nor the consummation of the transactions contemplated
hereby, will (i) violate any provision of the organizational documents of the Purchaser or violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any government,
governmental entity or court to which the Purchaser is subject, or (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of or creation of an encumbrance under, or create in any party the right to
accelerate, terminate, modify, or cancel, any agreement, contract, lease, license, instrument, or other arrangement to which the Purchaser is a party or by which the Purchaser is bound or to which the Purchaser’s assets are subject, in each
case of the foregoing (i) and (ii), in such a manner that would materially and adversely affect the Purchaser’s ability to consummate the transactions contemplated hereby. There is no action, suit or proceeding, pending or threatened
against the Purchaser that questions the validity of this Agreement or the right of the Purchaser to enter into this Agreement or to consummate the transactions contemplated hereby. 

(e) Consents and Approvals. Neither the execution and delivery by the Purchaser of this Agreement, nor the consummation by the
Purchaser of any of the transactions contemplated hereby, nor the performance by the Purchaser of this Agreement in accordance with its terms requires the consent, approval, order or authorization of, or registration with, or the giving notice to,
any governmental or public body or authority or any third party, except such as have been or will have been obtained, made or given on or prior to the Closing Date. 

  
 8 








 (f) Status and Investment Intent. 

(i) Experience. The Purchaser has sufficient knowledge and experience in financial and business matters so as to be
capable of evaluating the merits and risks of its investment in its Purchased Shares. The Purchaser is capable of bearing the economic risks of such investment, including a complete loss of its investment. 

(ii) Purchase Entirely for Own Account. The Purchaser is acquiring the Purchased Shares for its own account for
investment purposes only and not with the view to, or with any intention of, resale, distribution or other disposition thereof. The Purchaser does not have any direct or indirect arrangement, or understanding with any other persons to distribute, or
regarding the distribution of the Purchased Shares in violation of the Securities Act or any other applicable state securities law. 

(iii) Solicitation. The Purchaser (x) was not identified or contacted through the marketing of the Offering and
(y) did not contact the Company as a result of any general solicitation. 
 (iv) Information. The Purchaser has
been furnished access to all materials and information the Purchaser has requested relating to the Company and its Subsidiaries and other due diligence documents in order to evaluate the transactions contemplated by this Agreement. The Purchaser has
consulted to the extent deemed appropriate by the Purchaser with the Purchaser’s own advisers as to the financial, tax, legal and related matters concerning an investment in its Purchased Shares. 

(v) Not U.S. Person. The Purchaser is not a “U.S. person” as defined in Rule 902 of Regulation S. 

(vi) Offshore Transaction. The Purchaser has been advised and acknowledges that in issuing Purchased Shares to the
Purchaser pursuant hereto, the Company is relying upon the exemption from registration provided by Regulation S. The Purchaser is acquiring its Purchased Shares in an offshore transaction in reliance upon the exemption from registration provided by
Regulation S. 
 ARTICLE III 

COVENANTS 

Section 3.1 Lock-up. The Purchaser shall, at the Closing, enter into a lock-up agreement (the “Lock-up
Agreement”) in the form set forth in Exhibit A hereto. 
 Section 3.2 Distribution Compliance Period. The
Purchaser agrees not to resell, pledge or transfer any Purchased Shares within the United States or to any U.S. Person, as each of those terms is defined in Regulation S, during the 40 days following the Closing Date. 

Section 3.3 Registration Rights. The Company shall grant to the Purchaser customary registration rights with respect to the
Purchased Shares pursuant to a registration rights agreement to be mutually agreed in good faith as promptly as practicable after the date hereof and in no event later than the Closing Date. 

  
 9 








 Section 3.4 Further Assurances. From the date of this Agreement until the
Closing Date, the Company and the Purchaser shall use their reasonable best efforts to fulfill or obtain the fulfillment of the conditions precedent to the consummation of the transactions contemplated hereby. 

ARTICLE IV 

INDEMNIFICATION 

Section 4.1 Indemnification. Each of the Company and the Purchaser (an “Indemnifying Party”) shall
indemnify and hold each other and their directors, officers, employees, advisors and agents (collectively, the “Indemnified Party”) harmless from and against any losses, claims, damages, fines, expenses and liabilities of any kind
or nature whatsoever, including but not limited to any investigative, legal and other expenses incurred in connection with, and any amounts paid in settlement of, any pending or threatened legal action or proceeding, and any taxes or levies that may
be payable by such person by reason of the indemnification of any indemnifiable loss hereunder (collectively, “Losses”) resulting from or arising out of: (i) the breach of any representation or warranty of such Indemnifying
Party contained in this Agreement or in any schedule or exhibit hereto; or (ii) the violation or nonperformance, partial or total, of any covenant or agreement of such Indemnifying Party contained in this Agreement for reasons other than gross
negligence or willful misconduct of such Indemnified Party. In calculating the amount of any Losses of an Indemnified Party hereunder, there shall be subtracted the amount of any insurance proceeds and third-party payments received by the
Indemnified Party with respect to such Losses, if any. 
 Section 4.2 Third Party Claims. 

(a) If any third party shall notify any Indemnified Party in writing with respect to any matter involving a claim by such third party (a
“Third Party Claim”) which such Indemnified Party believes would give rise to a claim for indemnification against the Indemnifying Party under this Article IV, then the Indemnified Party shall promptly (i) notify the
Indemnifying Party thereof in writing within thirty (30) days of receipt of notice of such claim and (ii) transmit to the Indemnifying Party a written notice (“Claim Notice”) describing in reasonable detail the nature of
the Third Party Claim, a copy of all papers served with respect to such claim (if any), and the basis of the Indemnified Party’s request for indemnification under this Agreement. 

(b) Upon receipt of a Claim Notice with respect to a Third Party Claim, the Indemnifying Party shall have the right to assume the defense of
any Third Party Claim by, within (30) days of receipt of the Claim Notice, notifying the Indemnified Party in writing that the Indemnifying Party elects to assume the defense of such Third Party Claim, and upon delivery of such notice by the
Indemnifying Party, the Indemnifying Party shall have the right to fully control and settle the proceeding, provided, that, any such settlement or compromise shall be permitted hereunder only with the written consent of the Indemnified Party. 

  
 10 








 (c) If requested by the Indemnifying Party, the Indemnified Party shall, at the sole cost and
expense of the Indemnifying Party, cooperate with the Indemnifying Party and its counsel in contesting any Third Party Claim which the Indemnifying Party elects to contest, including the making of any related counterclaim against the person
asserting the Third Party Claim or any cross complaint against any person. The Indemnified Party shall have the right to receive copies of all pleadings, notices and communications with respect to any Third Party Claim, other than any privileged
communications between the Indemnifying Party and its counsel, and shall be entitled, at its sole cost and expense, to retain separate co-counsel and participate in, but not control, any defense or settlement of any Third Party Claim assumed by the
Indemnifying Party pursuant to Section 4.2(b). 
 (d) In the event of a Third Party Claim for which the Indemnifying Party
elects not to assume the defense or fails to make such an election within the 30 days of the Claim Notice, the Indemnified Party may, at its option, defend, settle, compromise or pay such action or claim at the expense of the Indemnifying Party;
provided, that, any such settlement or compromise shall be permitted hereunder only with the written consent of the Indemnifying Party, which consent shall not be unreasonably withheld or delayed. 

Section 4.3 Other Claims. In the event any Indemnified Party should have a claim against the Indemnifying Party hereunder
which does not involve a Third Party Claim, the Indemnified Party shall promptly transmit to the Indemnifying Party a written notice (the “Indemnity Notice”) describing in reasonable detail the nature of the claim, the Indemnified
Party’s best estimate of the amount of Losses attributable to such claim and the basis of the Indemnified Party’s request for indemnification under this Agreement. If the Indemnifying Party does not notify the Indemnified Party within
thirty (30) days from its receipt of the Indemnity Notice that the Indemnifying Party disputes such claim, the Indemnifying Party shall be deemed to have accepted and agreed with such claim. 

Section 4.4 Cap. Notwithstanding the foregoing, the Indemnifying Party shall have no liability (for indemnification or
otherwise) with respect to any Losses in excess of the applicable Purchase Price. 
 ARTICLE V 

MISCELLANEOUS 

Section 5.1 Survival of the Representations and Warranties. All representations and warranties made by any party hereto
shall survive for two years and shall terminate and be without further force or effect on the second anniversary of the date hereof, except as to (i) any claims thereunder which have been asserted in writing pursuant to Section 4.1 against
the party making such representations and warranties on or prior to such second anniversary, and (ii) the Company’s representations contained in Section 2.1(a), (b), (c), (d) and (e) hereof, each of which shall survive
indefinitely. 
 Section 5.2 Governing Law; Arbitration. This Agreement shall be governed and interpreted in accordance
with the laws of the State of New York without giving effect to the conflicts of law principles thereof. Any dispute arising out of or relating to this Agreement, including any question regarding its existence, validity or termination
(“Dispute”) shall be referred to and finally resolved by arbitration at the Hong Kong International Arbitration Centre in accordance with the Hong Kong International Arbitration Centre Administered Arbitration Rules then in force.
There shall be three arbitrators. Each Party has the right to appoint one arbitrator and the third arbitrator shall be appointed by the Hong Kong International Arbitration Centre. The language to be used in the arbitration proceedings shall be
English. The seat of arbitration shall be Hong Kong. Each of the Parties irrevocably waives any immunity to jurisdiction to which it may be entitled or become entitled (including without limitation sovereign immunity, immunity to pre-award
attachment, post-award attachment or otherwise) in any arbitration proceedings and/or enforcement proceedings against it arising out of or based on this Agreement or the transactions contemplated hereby. 

  
 11 








 Section 5.3 Amendment. This Agreement shall not be amended, changed or
modified, except by another agreement in writing executed by the parties hereto. 
 Section 5.4 Binding Effect. This
Agreement shall inure to the benefit of, and be binding upon, the Purchaser, the Company, and their respective heirs, successors and permitted assigns. 

Section 5.5 Assignment. Neither this Agreement nor any of the rights, duties or obligations hereunder may be assigned by
the Company or the Purchaser without the express written consent of the other Party, except that a Purchaser may assign all or any part of its rights and obligations hereunder to any affiliate of the Purchaser without the consent of the Company,
provided that no such assignment shall relieve the Purchaser of its obligations hereunder if such assignee does not perform such obligations. Any purported assignment in violation of the foregoing sentence shall be null and void. 

Section 5.6 Notices. All notices, requests, demands, and other communications under this Agreement shall be in writing and
shall be deemed to have been duly given on the date of actual delivery if delivered personally to the party hereto to whom notice is to be given, on the date sent if sent by telecopier, tested telex or prepaid telegram, on the next business day
following delivery to Federal Express properly addressed or on the day of attempted delivery by the U.S. Postal Service if mailed by registered or certified mail, return receipt requested, postage paid, and properly addressed as follows: 

 

			
	If to the Company, at:	  	Zhaopin Limited
		  	6/F, Fosun International Centre
		  	237 Chaoyang North Road
		  	Chaoyang District, Beijing 100020
		  	People’s Republic of China
		  	Attn: James Jianmin Guo
		
	With copy to:	  	Skadden, Arps, Slate, Meagher & Flom
		  	42/F Edinburgh Tower
		  	The Landmark
		  	15 Queen’s Road Central
		  	Fax: +852 3740 4863
		  	Attn: Z. Julie Gao, Esq. and Will H. Cai, Esq.
		
	If to the Purchaser, at:	  	PCV Belge SCS
		  	Rue Royale 97/4
		  	B-1000, Brussels
		  	Belgium
		  	Fax: +32 (0)2 209 22 99
		  	Attn: Jordan Temmerman and Christophe Tans
		
	With copy to:	  	Simpson Thacher & Bartlett LLP
		  	3919 China World Tower
		  	1 Jianguomenwai Avenue
		  	Chaoyang District, Beijing 100004
		  	Fax: +8610-5965 2988
		  	Attn: Douglas C. Markel, Esq.


  
 12 








 Any party hereto may change its address for purposes of this Section 5.6 by giving
the other Party written notice of the new address in the manner set forth above. 
 Section 5.7 Entire Agreement. This
Agreement together with the Lock-up Agreement constitutes the entire understanding and agreement between the Parties with respect to the matters covered hereby, and all prior agreements and understandings, oral or in writing, if any, between the
Parties with respect to the matters covered hereby are merged and superseded by such agreements. 
 Section 5.8
Severability. If any provisions of this Agreement shall be adjudicated to be illegal, invalid or unenforceable in any action or proceeding whether in its entirety or in any portion, then such provision shall be deemed amended, if
possible, or deleted, as the case may be, from the Agreement in order to render the remainder of the Agreement and any provision thereof both valid and enforceable, and all other provisions hereof shall be given effect separately therefrom and shall
not be affected thereby. 
 Section 5.9 Fees and Expenses. Except as otherwise provided in this Agreement, the Company
and the Purchaser will bear their respective expenses incurred in connection with the negotiation, preparation and execution of this Agreement and the transactions contemplated hereby, including fees and expenses of attorneys, accountants,
consultants and financial advisors. 
 Section 5.10 Confidentiality. Each party hereto shall keep in confidence, and
shall not use (except for the purposes of the transactions contemplated hereby) or disclose, any non-public information disclosed to it or its affiliates, representatives or agents in connection with this Agreement or the transactions contemplated
hereby. Each party hereto shall ensure that its affiliates, representatives and agents keep in confidence, and do not use (except for the purposes of the transactions contemplated hereby) or disclose, any such non-public information. 

Section 5.11 Specific Performance. The Parties agree that irreparable damage would occur in the event any provision of this
Agreement were not performed in accordance with the terms hereof and that the Parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or equity. 

Section 5.12 Termination. In the event that the Closing shall not have occurred by August 31, 2014, either the Company
or the Purchaser may terminate this Agreement with no further force or effect, except for the provisions of Article V, which shall survive any termination under this Section 5.12, provided that no party who is then in a material breach of this
Agreement shall not be entitled to terminate this Agreement. 

  
 13 








 Section 5.13 Description of Purchaser. 

(a) The Company shall afford the Purchaser a reasonable opportunity in which to review and comment on any description of the Purchaser and/or
the transactions contemplated by this Agreement that is to be included in any amendment to the Registration Statement filed after the date hereof, and the Company shall take into account such comments from Purchaser. 

(b) The Purchaser hereby consents and undertakes to promptly provide a description of its organization and business activities to the Company
(the “Purchaser Description”) to be used solely in any amendment to the Registration Statement and the prospectus therein, and hereby represents that the Purchaser Description will be true and accurate in all material respects and
will not be misleading in any material respect. Additionally, the Purchaser hereby consents to the filing of this Agreement as an exhibit to an amendment to the Registration Statement. Other than Purchaser Descriptions, the Company shall not include
in any amendment to the Registration Statement or the prospectus therein any information regarding the Purchaser without its prior written consent. 

(c) The Purchaser acknowledges that the Company will rely upon the truth and accuracy of the Purchaser Description, and it agrees to notify
the Company promptly in writing if any of the content contained therein ceases to be accurate and complete or becomes misleading. 

Section 5.14 Headings. The headings of the various articles and sections of this Agreement are inserted merely for the
purpose of convenience and do not expressly or by implication limit, define or extend the specific terms of the section so designated. 

Section 5.15 Execution in Counterparts. For the convenience of the Parties and to facilitate execution, this Agreement may
be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute but one and the same instrument. 

Section 5.16 No Waiver. Except as specifically set forth herein, the rights and remedies of the parties to this Agreement
are cumulative and not alternative. No failure or delay on the part of any party in exercising any right, power or remedy under this Agreement will operate as a waiver of such right, power or remedy, and no single or partial exercise of any such
right, power or remedy will preclude any other or further exercise of such right, power or remedy or the exercise of any other right, power or remedy. To the maximum extent permitted by applicable law, (a) no claim or right arising out of this
Agreement can be discharged by one party, in whole or in part, by a waiver or renunciation of the claim or right unless in writing signed by the other party; (b) no waiver that may be given by a party will be applicable except in the specific
instance for which it is given; and (c) no notice to or demand on one party will be deemed to be a waiver of any obligation of that party or of the right of the party giving such notice or demand to take further action without notice or demand
as provided in this Agreement. 
 [signatures follow] 

  
 14 








 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day
and year first above written. 
  

			
	ZHAOPIN LIMITED
		
	By:	 	 /s/ James Jianmin Guo

	Name:	 	James Jianmin Guo
	Title:	 	Chief Financial Officer


 [Signature Page to Subscription Agreement] 







 
							
	PCV BELGE SCS
				
	By:	 	/s/ Geoffrey Henry	 		 	/s/ Joanna Childs
		 	  

	Name:	 	Geoffrey Henry 	 	/     	 	Joanna Childs
	Title:	 	A Director	 		 	B Director


 [Signature Page to Subscription Agreement] 







 Schedule D-1 

Total Outstanding 
  

									
	 	  	Outstanding	 	  	Ordinary Shares
Upon Conversion
or Exercise	 
	 Series B convertible preferred shares
	  	 	257,166	  	  	 	257,166	  
	 Series C convertible preferred shares
	  	 	81,330	  	  	 	81,330	  
	 ordinary shares
	  	 	86,101,542	  	  	 	86,101,542	  
	 Options granted under the Company’s stock option plans as described in the Registration Statement (the “Option
Plans”) that are exercisable for ordinary shares
	  				  	 	17,166,259	  

 Authorized Share Capital 
  

													
	 Ordinary Shares
	  	 	159,051,299	  	  				  			
	 Preferred Shares
	  	 	119,263,199	  	  	 	consisting of:	  	  			
		  				  	 	Series A	  	  	 	12,604,286	  
		  				  	 	Series B	  	  	 	4,013,203	  
		  				  	 	Series C	  	  	 	15,722,878	  
		  				  	 	Series D-1	  	  	 	19,426,718	  
		  				  	 	Series D-2	  	  	 	4,687,500	  
		  				  	 	Series E	  	  	 	62,808,613	  


  
 1 








 Schedule D-2 

Total Outstanding Immediately After IPO 
  

			
	Class A Ordinary Shares consisting of:	  	
		  	The number of Class A Ordinary Shares issued in the IPO
		  	The number of Class A Ordinary Shares purchased by the Purchaser subject to the terms and conditions of the Subscription Agreement
		
	Class B Ordinary Shares	  	86,440,038
		
	Options granted in accordance with the Option Plans that are exercisable for Ordinary Shares	  	A number of options exercisable for no greater than 18,000,000 ordinary shares

 Authorized Share Capital Immediately After IPO 

 

					
	 Class A Ordinary Shares
	  	 	1,000,000,000	  
	 Class B Ordinary Shares
	  	 	100,000,000	  
	 Undesignated Shares
	  	 	900,000,000	  


  
 2